JPH0565824B2 - - Google Patents

Info

Publication number
JPH0565824B2
JPH0565824B2 JP59086153A JP8615384A JPH0565824B2 JP H0565824 B2 JPH0565824 B2 JP H0565824B2 JP 59086153 A JP59086153 A JP 59086153A JP 8615384 A JP8615384 A JP 8615384A JP H0565824 B2 JPH0565824 B2 JP H0565824B2
Authority
JP
Japan
Prior art keywords
slo
solution
latex
casein
aslo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59086153A
Other languages
Japanese (ja)
Other versions
JPS60231167A (en
Inventor
Mikiko Kumada
Masashi Seki
Hideaki Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissui Pharmacetuical Co Ltd
Original Assignee
Nissui Pharmacetuical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissui Pharmacetuical Co Ltd filed Critical Nissui Pharmacetuical Co Ltd
Priority to JP8615384A priority Critical patent/JPS60231167A/en
Publication of JPS60231167A publication Critical patent/JPS60231167A/en
Publication of JPH0565824B2 publication Critical patent/JPH0565824B2/ja
Granted legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56944Streptococcus

Description

【発明の詳細な説明】[Detailed description of the invention]

(産業上の利用分野) 本発明は診断用スクリーニング試薬に係り、殊
に溶連菌(溶血性連鎖球菌)感染症の診断のため
に使用されるスクリーニング試薬及びその調製法
に係る。 (従来の技術) SLO即ちストレプトリジンOはヒト由来連鎖
球菌の産生する溶血性毒素であつて抗原性を有し
ているために、溶連菌が体内でSLOを産生する
と、このSLOに対する抗体であるASLO(抗スト
レプトリジンO)が生成される。従つて、血清を
検体としてASLO価を測定する方法は溶連菌感染
症の診断法として汎用されるに至つている。 このASLO価測定法としては、従来ランツ−ラ
ンダール法が採用されて来た。この従来法は結果
が診断の根拠に供するに足るものとは云え、稀釈
度の異なる数種の血清液を必要とする面倒があ
り、又ASLO価測定処理方法も煩雑であると云う
欠陥を有していた。このランツ−ランダール法の
欠陥を幾分なりとも改善するために、マイクロタ
イター法が開発されたが、この方法においても稀
釈血清(1/10)を必要とし且つランツ−ランダー
ル法と同様にウサギ又はヒトO型赤血球浮遊液を
必要とする。 ASLO価を測定する上記両方法においてランツ
−ランダール法ではASLO価166単位を、又マイ
クロタイター法では160単位を基準として、これ
より下限値の場合には正常、上限値の場合には異
常と判断している。ここで留意すべきことは、診
断は、唯一回の検査で得られた値に基き下される
のではなく、臨床症状に応じ経過を追つて何回か
検査を行ないASLO価の推移変動を考慮してなさ
れる点にある。上記両従来法は正常値を示す検体
に関しても、異常値を示す検体に関しても、これ
らに関係なく同様の処理操作を必要とするもので
あり、検査能率の大幅な向上を期待することがで
きないと謂う欠陥を有している。 このために、正常値を示すことが明らかな検体
(陰性検体)と異常値を示す可能性のある検体
(陽性検体)とを判別する、所謂「スクリーニン
グ試薬」が研究開発され、陽性検体についての
み、上記の公知のASLO価測定法により精密測定
を行ない、これによつて検査能率の向上を達成し
ている。 現在知られているこの種のスクリーニング試薬
としては、ポリスチレンラテツクス粒子(以下単
に「ラテツクス」と称する)に直接的にSLOを
吸着させた懸濁液や、ラテツクスを牛血清アルブ
ミン溶液で予備処理してラテツクスへのSLOの
吸着を促進させたものがある。 溶血毒差であるSLOをラテツクスに直接的に
吸着させると、初期感作では活性が生じないか或
いは出現しても直ぐに失われてしまうので、活性
をもたらすためには感作回数を増す必要性があ
り、例えば1600単位のSLO溶液で2〜3回感作
させてSLO活性が初めて出現する程度であり、
その吸着量は甚だ低い。吸着促進剤として前記の
牛血清アルブミンを用いてラテツクスを処理する
場合にも、1600単位のSLO溶液を用いる感作で
1回だけでは吸着量が低く、従つて数回の感作処
理を必要としていた。1回の感作処理に通例30分
間程度の処理時間を要するのみならずラテツクス
へのSLOの上限吸着量を然程高くなし得なかつ
たのが実情であり、このためにASLO価測定開始
前に検体を稀釈するか或いはSLO溶液により検
体中のASLOを中和する必要性があつた。 (発明が解決しようとする問題点) 従来のスクリーニング試薬における除上の問題
点に鑑みて、本発明は先ず第1にラテツクスへの
SLOの吸着性を高め、これによつて感作処理回
数の減少延いては処理時間及び労力を節減し、稀
釈SLOの使用可能性(コストダウン)をもたら
し、更には検定に際して被検血清を稀釈したり又
はSLO溶液による中和を行なう必要性を無から
しめようとするものである。 本発明が解決しようとしている第2の問題点は
検定結果の信頼度が極めて高く、従つて陰性検体
と陽性検体とが明確に区別でき、これにより良好
なスクリーニングをもたらそうとするものであ
る。 (問題点を解決するための手段及び作用) 上記の目的を達成するための本発明による診断
用スクリーニング試薬は、ラテツクス粒子への
SLO吸着促進剤がカゼインであることを特徴と
している。 本発明方法によれば、この診断用スクリーニン
グ試薬は、ラテツクス粒子をカゼイン溶液で予備
処理し、次いでSLO溶液で感作させることによ
り調製することができる。 SLO吸着促進剤としてカゼインを用い、本発
明方法に従つて、このカゼイン溶液でラテツクス
を予備処理し、次いでSLO溶液をラテツクスに
吸着させると、該ラテツクスは吸着促進物質とし
て従来の牛血清アルブミンを使用した場合と比較
して5〜10倍のSLO活性を示し、このために従
来では1600単位のSLO溶液で2〜3回感作処理
することが必要とされて来たのが、本発明によれ
ば800単位のSLO溶液による1回感作で従来より
も高いSLO活性を発現させることができ、従つ
て処理に関する時間の短縮及びコストの著るしい
低減が達成される。 更に、本発明によるスクリーニング試薬はマイ
クロタイター法によるASLO価が160以上の検体
に関して極めて明確な凝集(陽性)反応を示し且
つASLO価が160以下の検体に関しては非凝集
(陰性)反応を示し、この場合にASLO価160以上
の検体に関して陰性反応を示すことはない。この
ことは本発明による試薬がスクリーニング目的に
極めて好適であることを示している。 (調製例及び試験例) 次に、本発明によるスクリーニング試薬の調製
例並びにSLO活性、検定結果とマイクロタイタ
ー法により測定されたASLO価との相関試験等に
関連して本発明を更に詳細に説明する。 調製例 1 (1) 前処理 10mM燐酸緩衝液(PH7.4)を用いて次の溶
液を調製する。 (a) 5%ポリスチレンラテツクス液 (ラテツクスとしては日本合成ゴム株式会社
のTMMUTEX−商標−を使用) (b) 0.5%カゼイン溶液 (カゼインとしてはメルク社製の
HAMMARSTEN−商標−を使用) (c) 800単位のSLO溶液 (2) 試薬調製 上記ラテツクス液(a)及びカゼイン溶液(b)を各
2ml宛採取して混合し、37℃で60分間インキユ
ベートした後に30000×gで20分間遠心して上
清を除去し、次いで上記緩衝液を用いて全量を
2mlとなした。 得られたカゼイン処理ラテツクス(5%)液
を1%に稀釈し、上記SLO溶液(c)2mlを採取
添加し、室温で30分間インキユベートした後に
遠心して上清を除去し、次いで上記緩衝液を用
いて全量を2mlとし、音波振動により分散させ
て試薬となした。 調製例 2 調製例1と同様にして、但し5%ラテツクス液
の代りに0.5%ラテツクス液を使用し0.5%カゼイ
ン液で予備感作(37℃、60分)させた処、同様の
試薬が得られた。 SLO活性試験例 ポリスチレンラテツクスに直接的にSLOを感
作させた場合、吸着促進剤として周知の牛血清ア
ルブミンを使用してSLOを感作させた場合及び
本発明に従い吸着促進剤としてカゼインを使用し
てSLOを感作させた場合につき、ラテツクス試
薬のSLO活性と感作回数との関係を調べた処、
第1図のグラフに示される如き結果が得られた。 尚、このSLO活性試験において、未処理ラテ
ツクスの場合()及び牛血清アルブミン処理ラ
テツクスの場合()に関して使用されたSLO
溶液は1600単位のものであり、一方カゼイン処理
ラテツクスの場合()に関して使用された
SLO溶液は調製例において使用されている800単
位のものであつた。 第1図のグラフから明らかなように、本発明に
従つてカゼインで予備感作させたラテツクスは
800単位のSLO液による1回感作で約1000単位の
SLO活性を示し、従つて160単位程度が問題とな
る被検血清のスクリーニング試薬として充分以上
の感度をもたらし得ることが判り、一方未処理ラ
テツクスや牛血清アルブミン処理ラテツクスでは
感作処理回数を相当増さねば必要とされる感度を
達成し得ないことが判つた。 マイクロタイター法により測定されたASLO価と
判定結果との相関試験 () 本発明によるスクリーニング試薬 各被検血清につき、調製例1によるスクリー
ニング試薬を用い下記要領で判定した。 試験方法: 被検血清50μをスライド板上に滴下し、こ
れにスクリーニング試薬を50μ添加して充分
に混合した後に、スライド板をローリングし、
3分後に下記4段階法で判定する。 −:凝集が認められない ±:凝集が定かでない +:若干の凝集が認められる ++:顕著な凝集が認められる () 某社から市販のスクリーニング試薬 各被検血清につき、某社から市販のスクリー
ニング試薬を用い下記要領で判定した。 試験方法: 被検血清10μをスライドを板上に滴下し、
これに血清稀釈液(緩衝液)を0.05ml添加して
充分に混和する。次いでスクリーニング試薬
0.025mlを採取添加し、スライド板を15秒程ロ
ーリングして混和した後水平回転機(80〜
100rpm)に移し又はローリング混和を継続し
て反応させ、上記スクリーニング試薬添加後3
分後に、上記第()項と同様に4段階法で判
定した。 () マイクロタイター法によるASLO価測定上
記第()及び()項で試験に供した各血清
につき、常法に従いマイクロタイター法を使用
してASLO価を測定した。 () 相関試験 上記第()項で得た判定結果と上記第
()項で得たASLO価測定結果とをグラフに
プロツトした処第2図に示される結果が得ら
れ、一方上記第()項で得た判定結果と上記
第()項で得たASLO価測定結果とをグラフ
にプロツトした処第3図に示される結果が得ら
れた。 第2図と第3図とを比較すれば明らかなよう
に、本発明によるスクリーニング試薬は、異常
か正常かを判断すべきASLO価160単位を境に
し、それより下限値では明らかな陰性反応を呈
し、それより上限値では明らかな陽性反応を呈
し、従つて感度が高く信頼性に優れていること
が判り、一方従来公知のスクリーニング試薬で
はASLO価が高いにも拘らず陰性乃至疑陽性反
応を呈する場合があるので、信頼性が低いこと
が判る。 カゼインの種類がSLO活性に及ぼす影響 本発明に使用されるSLO吸着促進剤としてカ
ゼインが、その種類に依存してラテツクス粒子へ
のSLO吸着能に差異が生じるか否かを確認する
ために、市販の各種カゼンインにつき検討した結
果は下表に示される通りであり有意の差は認めら
れなかつた。 尚、電気泳動法による試薬も試みたが、蛋白質
及び脂質の永動パターンにカゼインの種類に基因
する違いは認められなかつた。
(Industrial Application Field) The present invention relates to a diagnostic screening reagent, and particularly to a screening reagent used for diagnosing streptococcal infections and a method for preparing the same. (Prior art) SLO, or streptolysin O, is a hemolytic toxin produced by human-derived streptococci and has antigenicity. Therefore, when streptococci produce SLO in the body, ASLO, an antibody against this SLO, (anti-streptolysin O) is produced. Therefore, the method of measuring the ASLO value using serum as a specimen has come to be widely used as a diagnostic method for streptococcal infections. Conventionally, the Lanz-Randall method has been adopted as the ASLO value measurement method. Although the results of this conventional method are sufficient to provide a basis for diagnosis, it has the drawbacks of requiring several types of serum fluids with different dilutions, and that the ASLO titer measurement processing method is also complicated. Was. The microtiter method was developed to improve some of the deficiencies of the Lanz-Randahl method, but this method also requires diluted serum (1/10) and, like the Lanz-Randahl method, requires rabbit or rabbit serum. Requires human type O red blood cell suspension. In both of the above methods of measuring ASLO value, the standard is ASLO value 166 units for the Lanz-Randahl method and 160 units for the microtiter method.If the value is lower than this, it is considered normal, and if it is the upper limit, it is considered abnormal. are doing. It should be noted here that the diagnosis is not based on the value obtained in a single test, but rather takes into account changes in the ASLO value by performing tests several times over time depending on the clinical symptoms. The point is that it is done. Both of the above conventional methods require the same processing operations regardless of whether the sample shows a normal value or the sample shows an abnormal value, and therefore cannot be expected to significantly improve testing efficiency. It has the so-called defect. For this purpose, so-called "screening reagents" have been researched and developed to distinguish between samples that clearly show normal values (negative samples) and samples that may show abnormal values (positive samples). , the above-mentioned well-known ASLO value measurement method is used to perform precise measurements, thereby achieving an improvement in inspection efficiency. Currently known screening reagents of this type include suspensions in which SLO is directly adsorbed onto polystyrene latex particles (hereinafter simply referred to as "latex"), and latex pre-treated with a bovine serum albumin solution. There are some methods that have promoted the adsorption of SLO to latex. When SLO, which is a hemolytic toxin, is directly adsorbed to latex, no activity occurs during initial sensitization, or even if it appears, it is quickly lost, so it is necessary to increase the number of sensitizations to bring about activity. For example, SLO activity only appears after 2 to 3 sensitizations with 1600 units of SLO solution.
Its adsorption amount is extremely low. Even when latex is treated with the aforementioned bovine serum albumin as an adsorption promoter, the amount of adsorption is low after only one sensitization using 1600 units of SLO solution, and therefore several sensitization treatments are required. there was. The reality is that not only does one sensitization treatment usually take about 30 minutes, but the upper limit of SLO adsorption to latex cannot be achieved at a sufficiently high level. It was necessary to dilute the specimen or neutralize ASLO in the specimen with an SLO solution. (Problems to be Solved by the Invention) In view of the problems of removal in conventional screening reagents, the present invention first solves
Increases the adsorption of SLO, thereby reducing the number of sensitization treatments, which in turn saves processing time and labor, making it possible to use diluted SLO (reducing costs), and further diluting the test serum during assay. It is intended to eliminate the need for neutralization with SLO solution. The second problem that the present invention aims to solve is that the reliability of the assay results is extremely high, so that negative samples and positive samples can be clearly distinguished, which leads to better screening. . (Means and effects for solving the problems) The diagnostic screening reagent according to the present invention for achieving the above-mentioned purpose has the following properties:
It is characterized in that the SLO adsorption promoter is casein. According to the method of the invention, this diagnostic screening reagent can be prepared by pre-treating latex particles with a casein solution and then sensitizing them with an SLO solution. If casein is used as the SLO adsorption promoter and the latex is pretreated with this casein solution according to the method of the present invention and then the SLO solution is adsorbed onto the latex, the latex uses conventional bovine serum albumin as the adsorption promoter. The present invention shows 5 to 10 times more SLO activity compared to the sensitized SLO solution, which conventionally required 2 to 3 sensitization treatments with 1600 units of SLO solution. For example, a single sensitization with 800 units of SLO solution can produce a higher SLO activity than ever before, thus achieving a significant reduction in processing time and costs. Furthermore, the screening reagent according to the present invention shows a very clear agglutination (positive) reaction for specimens with an ASLO value of 160 or more by microtiter method, and a non-agglutination (negative) reaction for specimens with an ASLO value of 160 or less, and this In some cases, a negative reaction will not be shown for specimens with an ASLO value of 160 or higher. This shows that the reagent according to the invention is highly suitable for screening purposes. (Preparation Examples and Test Examples) Next, the present invention will be explained in more detail in connection with preparation examples of screening reagents according to the present invention, SLO activity, correlation tests between assay results and ASLO values measured by the microtiter method, etc. do. Preparation Example 1 (1) Pretreatment Prepare the following solution using 10mM phosphate buffer (PH7.4). (a) 5% polystyrene latex solution (TMMUTEX trademark of Japan Synthetic Rubber Co., Ltd. is used as the latex) (b) 0.5% casein solution (as the casein, TMMUTEX manufactured by Nippon Gosei Rubber Co., Ltd. is used)
(Use HAMMARSTEN - Trademark -) (c) 800 units of SLO solution (2) Reagent preparation Collect 2 ml each of the latex solution (a) and casein solution (b) above, mix them, and incubate at 37°C for 60 minutes. The supernatant was removed by centrifugation at 30,000×g for 20 minutes, and the total volume was made up to 2 ml using the above buffer. The obtained casein-treated latex (5%) solution was diluted to 1%, 2 ml of the above SLO solution (c) was collected and added, and after incubation at room temperature for 30 minutes, centrifugation was performed to remove the supernatant, and then the above buffer solution was added. The total volume was 2 ml, and the reagent was dispersed by sonic vibration. Preparation Example 2 A similar reagent was obtained in the same manner as Preparation Example 1, except that 0.5% latex solution was used instead of 5% latex solution, and presensitization was performed with 0.5% casein solution (37°C, 60 minutes). It was done. SLO activity test example: When polystyrene latex is directly sensitized with SLO, when SLO is sensitized using bovine serum albumin, which is well known as an adsorption promoter, and when casein is used as an adsorption promoter according to the present invention. We investigated the relationship between the SLO activity of the latex reagent and the number of sensitizations when SLO was sensitized using
The results shown in the graph of FIG. 1 were obtained. In addition, in this SLO activity test, the SLO used in the case of untreated latex () and the case of bovine serum albumin-treated latex ()
The solution was of 1600 units, while in case of casein-treated latex () was used for
The SLO solution was the 800 units used in the preparation examples. As is clear from the graph in FIG. 1, the latex presensitized with casein according to the present invention
A single sensitization with 800 units of SLO solution produces approximately 1000 units of
It has been found that around 160 units of SLO activity can provide more than sufficient sensitivity as a screening reagent for the test serum in question, while untreated latex and latex treated with bovine serum albumin require a considerable increase in the number of sensitization treatments. It was found that otherwise the required sensitivity could not be achieved. Correlation test between ASLO value measured by microtiter method and determination results () Screening reagent according to the present invention Each test serum was determined in the following manner using the screening reagent according to Preparation Example 1. Test method: Drop 50μ of the test serum onto the slide plate, add 50μ of the screening reagent to this, mix thoroughly, and then roll the slide plate.
Judgment is made after 3 minutes using the following 4-step method. −: No agglutination ±: Uncertain agglutination +: Some agglutination ++: Significant agglutination () Commercially available screening reagent from a certain company For each serum to be tested, use a commercially available screening reagent from a certain company. It was determined according to the following procedure. Test method: Drop 10μ of the test serum onto the slide.
Add 0.05 ml of serum diluent (buffer) to this and mix thoroughly. Then screening reagent
Collect and add 0.025ml, mix by rolling the slide plate for about 15 seconds, and then use a horizontal rotating machine (80~
100 rpm) or continue rolling mixing to react, and after adding the above screening reagent 3.
After a few minutes, the test was carried out using the four-step method as described in section () above. () ASLO titer measurement using the microtiter method The ASLO titer was measured for each serum tested in paragraphs () and () above using the microtiter method according to a conventional method. () Correlation test The results shown in Figure 2 are obtained by plotting the judgment results obtained in section () above and the ASLO value measurement results obtained in section () above on a graph, while the results shown in section () above are obtained. The results shown in FIG. 3, which is a graph plotting the determination results obtained in Section 1 and the ASLO value measurement results obtained in Section () above, were obtained. As is clear from a comparison of Figures 2 and 3, the screening reagent of the present invention has an ASLO titer of 160 units, which is the threshold for determining whether it is abnormal or normal, and below which a clear negative reaction is not observed. At the upper limit value, a clear positive reaction is obtained, indicating that the reagent has high sensitivity and excellent reliability.On the other hand, conventional screening reagents give a negative or false positive reaction despite the high ASLO value. It can be seen that the reliability is low. Effect of casein type on SLO activity In order to confirm whether the SLO adsorption ability of casein to latex particles differs depending on the type of casein used as the SLO adsorption promoter used in the present invention, commercially available casein was used as an SLO adsorption promoter. The results of examining various casein are shown in the table below, and no significant differences were observed. Although reagents using electrophoresis were also tried, no differences were observed in the migration patterns of proteins and lipids based on the type of casein.

【表】 試験例 1 (吸着促進剤の濃度とSLO活性との関係) 10mM燐酸緩衝液(PH7.4)を用いて調製され
た5%ポリスチレンラテツクス液を超音波処理し
てラテツクス液を調製した。 このラテツクス液1mlに対して、1mlのカゼイ
ン液(0.1、0.5、1.0又は2.0%)或は対照として
の牛血清アルブミン液(0.1、0.5、1.0又は2.0%)
を添加し、室温において60分間インキユベート
し、次いで1500rpmで20分間遠心して上清を除去
することにより予備感作ラテツクスを得た。 各予備感作ラテツクスに上記の緩衝液を添加し
て全量を5mlとなし、これに800単位のSLO溶液
5mlを添加し、室温において30分間インキユベー
トし、1500rpmで60分間遠心して上清を除去し、
これに上記の緩衝液を添加して全量を5mlとな
し、次いで超音波処理することによりSLO感作
ラテツクス試薬を得た。 これらの各SLO感作ラテツクス試薬における
SLO活性を調べた結果は第4図のグラフに示さ
れる通りであり、カゼインの場合には濃度が低い
場合にも高いSLO吸着効果を示し、一方牛血清
アルブミンの場合には濃度を上昇させてもSLO
吸着効果は余り高くならないことが判る。 試験例 2 試験例1と同様に、但しSLOの吸着促進剤と
して1%のカゼイン、卵アルブミン又は牛血清ア
ルブミン液を使用して予備感作ラテツクス液を調
製し、このラテツクス液と等量のSLO溶液(800
単位)とを用いて5回感作させることにより
SLO感作ラテツクス試薬を調製した。 これらの各SLO感作ラテツクス試薬のSLO活
性を調べ、カゼインを予備感作させた試薬が示す
SLO活性を100%として相対値を算出した処、予
備感作のために卵アルブミンを用いた場合には50
%であり、又牛血清アルブミンを用いた場合には
13%であり、カゼインによるSLO吸着効果が有
意に優れていることが判明した。
[Table] Test example 1 (Relationship between adsorption promoter concentration and SLO activity) A latex solution was prepared by ultrasonicating a 5% polystyrene latex solution prepared using 10mM phosphate buffer (PH7.4). did. For 1 ml of this latex solution, 1 ml of casein solution (0.1, 0.5, 1.0 or 2.0%) or bovine serum albumin solution (0.1, 0.5, 1.0 or 2.0%) as a control.
was added, incubated for 60 minutes at room temperature, and then centrifuged at 1500 rpm for 20 minutes to remove the supernatant to obtain a pre-sensitized latex. Add the above buffer to each presensitized latex to make a total volume of 5 ml, add 5 ml of 800 units of SLO solution, incubate at room temperature for 30 minutes, centrifuge at 1500 rpm for 60 minutes, and remove the supernatant. ,
The above buffer solution was added to make the total volume 5 ml, followed by ultrasonication to obtain an SLO sensitized latex reagent. In each of these SLO sensitized latex reagents,
The results of investigating SLO activity are as shown in the graph in Figure 4. Casein shows a high SLO adsorption effect even when the concentration is low, while bovine serum albumin shows a high SLO adsorption effect when the concentration is increased. Also SLO
It can be seen that the adsorption effect is not very high. Test Example 2 In the same manner as Test Example 1, however, a presensitization latex solution was prepared using 1% casein, egg albumin, or bovine serum albumin solution as an adsorption promoter for SLO, and an equal amount of SLO was prepared in the same manner as in Test Example 1. Solution (800
unit) by sensitizing 5 times using
A SLO sensitized latex reagent was prepared. The SLO activity of each of these SLO-sensitized latex reagents was investigated, and the reagents pre-sensitized with casein exhibited
The relative value was calculated assuming SLO activity as 100%, and when ovalbumin was used for presensitization, it was 50%.
%, and when using bovine serum albumin
It was found that the SLO adsorption effect by casein was significantly superior.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図はSLOの吸着促進剤としてカゼインを
用いた場合及び牛血清アルブミンを用いた場合並
びに吸着促進剤を用いない場合におけるSLOの
感作回数とラテツクスのSLO活性との関係を示
すグラフであり、第2図は本発明によるスクリー
ニング試薬を用いた場合の判定結果とマイクロタ
イター法によるASLO価測定結果との関係を示す
グラフであり、第3図は市販のスクリーニング試
薬を用いた場合の判定結果とマイクロタイター法
によるASLO価測定結果との関係を示すグラフで
あり、第4図はSLOの吸着促進剤としてカゼイ
ン又は牛血清アルブミンを種々の濃度で用いてラ
テツクスを予備感作させ、次いでSLOを感作さ
せた場合における吸着促進剤濃度とSLO活性と
の関係を示すグラフである。
Figure 1 is a graph showing the relationship between the number of SLO sensitizations and the SLO activity of latex when casein is used as an adsorption promoter for SLO, when bovine serum albumin is used, and when no adsorption promoter is used. , FIG. 2 is a graph showing the relationship between the judgment results when using the screening reagent according to the present invention and the ASLO titer measurement results by the microtiter method, and FIG. 3 is a graph showing the judgment results when using the commercially available screening reagent. FIG. 4 is a graph showing the relationship between the results of ASLO titer measurement using the microtiter method. FIG. It is a graph showing the relationship between adsorption promoter concentration and SLO activity in the case of sensitization.

Claims (1)

【特許請求の範囲】 1 ラテツクス粒子へのSLO吸着促進剤がカゼ
インであることを特徴とする、診断用スクリーニ
ング試薬。 2 ラテツクス粒子をカゼイン溶液で予備処理
し、次いでSLO溶液で感作させることを特徴と
する、診断用スクリーニング試薬の調製法。
[Scope of Claims] 1. A diagnostic screening reagent, characterized in that the SLO adsorption promoter to latex particles is casein. 2. A method for preparing a diagnostic screening reagent, which comprises pretreating latex particles with a casein solution and then sensitizing them with an SLO solution.
JP8615384A 1984-05-01 1984-05-01 Diagnostic screening reagent and preparation thereof Granted JPS60231167A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8615384A JPS60231167A (en) 1984-05-01 1984-05-01 Diagnostic screening reagent and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8615384A JPS60231167A (en) 1984-05-01 1984-05-01 Diagnostic screening reagent and preparation thereof

Publications (2)

Publication Number Publication Date
JPS60231167A JPS60231167A (en) 1985-11-16
JPH0565824B2 true JPH0565824B2 (en) 1993-09-20

Family

ID=13878790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8615384A Granted JPS60231167A (en) 1984-05-01 1984-05-01 Diagnostic screening reagent and preparation thereof

Country Status (1)

Country Link
JP (1) JPS60231167A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0735393U (en) * 1993-12-13 1995-06-27 有限会社フタバ産業 Video cassette mail storage box
JP2013145172A (en) * 2012-01-13 2013-07-25 Sysmex Corp Method of detecting adrenal cortical stimulating hormone, and absorbent
KR101428492B1 (en) * 2013-08-30 2014-08-12 린나이코리아 주식회사 Safety system for overheat in boiler

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3882058T2 (en) * 1987-02-27 1994-01-13 Eastman Kodak Co Immunoreactive reagent, process for its preparation and its use in the determination of an immunoreactive species.
US4847199A (en) * 1987-02-27 1989-07-11 Eastman Kodak Company Agglutination immunoassay and kit for determination of a multivalent immune species using a buffered salt wash solution
US5120643A (en) * 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
CN106153887A (en) * 2016-05-27 2016-11-23 安徽伊普诺康生物技术股份有限公司 A kind of kit measuring antistreptolysin O

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5531960A (en) * 1978-08-30 1980-03-06 Nitsusui Seiyaku Kk Latex sensing for cohesion reaction
JPS58172552A (en) * 1982-03-19 1983-10-11 ベ−リングヴエルケ・アクチエンゲゼルシヤフト Anti-streptolysin o-latex reagent and its manufacture

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5531960A (en) * 1978-08-30 1980-03-06 Nitsusui Seiyaku Kk Latex sensing for cohesion reaction
JPS58172552A (en) * 1982-03-19 1983-10-11 ベ−リングヴエルケ・アクチエンゲゼルシヤフト Anti-streptolysin o-latex reagent and its manufacture

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0735393U (en) * 1993-12-13 1995-06-27 有限会社フタバ産業 Video cassette mail storage box
JP2013145172A (en) * 2012-01-13 2013-07-25 Sysmex Corp Method of detecting adrenal cortical stimulating hormone, and absorbent
KR101428492B1 (en) * 2013-08-30 2014-08-12 린나이코리아 주식회사 Safety system for overheat in boiler

Also Published As

Publication number Publication date
JPS60231167A (en) 1985-11-16

Similar Documents

Publication Publication Date Title
Dominguez et al. Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples
WO2018129885A1 (en) Detection kit for whole blood c-reactive protein
JP2901296B2 (en) Preparation of Campylobacter pylori macromolecular cell-associated protein and its use for serological detection of Campylobacter pylori infection
CA1139203A (en) Method and reagent for counteracting lipemic interference
KR880001533B1 (en) Measuring method for reaction of the entigen and the antibody
Gray et al. Experience with the use of pronase to eliminate interference factors in the latex agglutination test for cryptococcal antigen
US4711841A (en) Method for determining one or more antigens in a sample
US4814247A (en) Method for determining the existance and/or the monitoring of a pathological condition in a mammal
JPH0565824B2 (en)
Castellano et al. Evaluation of commercially available diagnostic test kits for rubella
JPH0214661B2 (en)
Jenkins et al. Detection of meningitis antigens in buffer and body fluids by ultrasound-enhanced particle agglutination
Marx Jr et al. Comparison of the enzyme-linked immunosorbent assay and double immunodiffusion test for the detection and quantitation of antibodies in farmer's lung disease
Beda-Maluga et al. The detection of macroprolactin by precipitation and ultrafiltration methods
JP3752219B2 (en) Identification method of dementia disease
EP0770875B1 (en) Marker and reagent for diabetes mellitus and diabetes mellitus complication
JPH07140144A (en) Method for measuring allergen specific ige antibody and antigen-antibody complex
Lagneau et al. Fluid therapy directly interferes with immunoassay for cardiac troponin I
US4090846A (en) Indirect latex test for determination of fibrinogen degradation products
Fayram et al. Fluorescence immunoassay and passive latex agglutination as alternatives to hemagglutination inhibition for determining rubella immune status
Lange et al. INTERPRETATION OF FINDINGS IN THE CEREBROSPINAL FLUID: I. THE DEMENTIA PARALYTIGA FORMULA AND THE NECESSITY OF ITS QUANTITATIVE DIFFERENTIATION
Knight New enzyme immunoassay for detecting cryptococcal antigen.
Nicolet et al. ELISA in large animals
JPS63196855A (en) Specific immunoassay
CN113049837A (en) Whole blood PCT immunoturbidimetric reagent